Sanofi
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after being featured as ...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, E...
Latest News
10 days ago · seekingalpha.com
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 3.7%, we present two other groups of five DGI stocks, each with moderate to high yields of up to 8%.
13 days ago · globenewswire.com
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.
14 days ago · zacks.com
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone RevenuesRXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.
18 days ago · marketbeat.com
Sanofi Q3 Earnings Call HighlightsSanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. The company also raised its full-year sales and business EPS outlook while outlining a strategy focused on immunology, rare diseases and vaccines.
18 days ago · benzinga.com
Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without ItSanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increased 16.2% year over year, up 14.3% in constant currency.
18 days ago · 247wallst.com
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks UpA strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.
18 days ago · zacks.com
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares RiseSNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.
18 days ago · wsj.com
Sanofi CEO Sets Sights on Deals to Drive TurnaroundThe French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.
22 days ago · 247wallst.com
Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 EarningsRegeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.
22 days ago · seekingalpha.com
Sanofi: An Alluring And Balanced Mix Of Yield And GrowthSanofi has increased its dividend for 31 consecutive years. It's only because this is not an American company in the S&P 500 that it's not a dividend aristocrat. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compound annual growth rate of 2.6%. Sanofi has a great financial position. The long-term debt/equity ratio is 0.2, while the interest coverage ratio is 11.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SNY